Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03678545 · ClinicalTrials.gov registry record · Phase 2
Dupilumab in Eosinophilic Gastritis
A Phase 2 study, sponsored by Children's Hospital Medical Center, Cincinnati.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT03678545 is a Phase 2 study that has completed, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 41 participants.
The verdict
NCT03678545, a Phase 2 study, has completed, sponsored by Children's Hospital Medical Center, Cincinnati.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
40 participants with Eosinophilic Gastritis 12-70 years of age will be randomly assigned with dupilumab or placebo subcutaneous injections every two weeks for a total of 12 weeks. Study subjects who complete the 12-week treatment phase, may continue into an open label extension study, where dupilumab will be administered every two weeks for a total of 24 weeks.
Interventions
- DRUG Placebo (blinded)
- DRUG Dupilumab (blinded)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2021-05-15 |
| Est. Completion | 2024-11-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03678545
The ClinicalTrials.gov registry entry for NCT03678545 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo (blinded) is the first listed.
NCT03678545 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03678545 about?
NCT03678545 is a clinical study titled "Dupilumab in Eosinophilic Gastritis". 40 participants with Eosinophilic Gastritis 12-70 years of age will be randomly assigned with dupilumab or placebo subcutaneous injections every two weeks for a total of 12 weeks. Study subjects who complete the 12-week treatment phase, may continue into an open label extension study, where dupiluma...
What is the current status of trial NCT03678545?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2021-05-15. Estimated completion is 2024-11-13.
What interventions are being tested in trial NCT03678545?
The interventions under investigation include: Placebo (blinded) (DRUG), Dupilumab (blinded) (DRUG).
Who is sponsoring clinical trial NCT03678545?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.